Business Description
Tharimmune Inc
NAICS : 325412
SIC : 2834
ISIN : US4327052001
Description
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.79 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -13.9 | |||||
3-Year EPS without NRI Growth Rate | -14.7 | |||||
3-Year FCF Growth Rate | -32.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.67 | |||||
9-Day RSI | 52.55 | |||||
14-Day RSI | 48.82 | |||||
6-1 Month Momentum % | -38.91 | |||||
12-1 Month Momentum % | -95.79 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.84 | |||||
Quick Ratio | 4.84 | |||||
Cash Ratio | 4.58 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -196.6 | |||||
Shareholder Yield % | -299.36 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -183.56 | |||||
ROA % | -137.48 | |||||
ROIC % | -2840 | |||||
ROC (Joel Greenblatt) % | -4620.31 | |||||
ROCE % | -183.23 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.39 | |||||
Price-to-Tangible-Book | 0.39 | |||||
EV-to-EBIT | -0.12 | |||||
EV-to-EBITDA | -0.12 | |||||
EV-to-FCF | -0.16 | |||||
Price-to-Net-Current-Asset-Value | 0.4 | |||||
Price-to-Net-Cash | 0.43 | |||||
Earnings Yield (Greenblatt) % | -833.33 | |||||
FCF Yield % | -240.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:THAR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tharimmune Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -107.261 | ||
Beta | 0 | ||
Volatility % | 79.93 | ||
14-Day RSI | 48.82 | ||
14-Day ATR ($) | 0.452428 | ||
20-Day SMA ($) | 5.160429 | ||
12-1 Month Momentum % | -95.79 | ||
52-Week Range ($) | 3.4999 - 163.087497 | ||
Shares Outstanding (Mil) | 0.79 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Tharimmune Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Tharimmune Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Tharimmune Inc Frequently Asked Questions
What is Tharimmune Inc(THAR)'s stock price today?
The current price of THAR is $3.53. The 52 week high of THAR is $163.09 and 52 week low is $3.50.
When is next earnings date of Tharimmune Inc(THAR)?
The next earnings date of Tharimmune Inc(THAR) is 2024-08-09 Est..
Does Tharimmune Inc(THAR) pay dividends? If so, how much?
Tharimmune Inc(THAR) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |